E2 ModerateModerate confidencePEM ✗Machine draft
Proteomics and cytokine analyses distinguish myalgic encephalomyelitis/chronic fatigue syndrome cases from controls.
Giloteaux, Ludovic, Li, Jiayin, Hornig, Mady et al. · Journal of translational medicine · 2023 · DOI
Quick Summary
Researchers studied tiny particles called extracellular vesicles found in the blood of ME/CFS patients and compared them to healthy controls. They found that ME/CFS patients had more of these particles and they contained different levels of immune chemicals, particularly one called IL2. Using computer algorithms to analyze 20 different blood proteins, they could correctly identify ME/CFS patients about 86% of the time, suggesting that blood tests might one day help diagnose this condition.
Why It Matters
This research provides objective biomolecular evidence supporting ME/CFS as a disease with measurable physiological abnormalities, moving beyond subjective symptom reporting. The identification of potential blood-based biomarkers could facilitate earlier diagnosis and enable stratification of ME/CFS subtypes, while the immune and hemostasis pathway findings suggest specific therapeutic targets worth investigating.
Observed Findings
- ME/CFS cases exhibited significantly greater size and concentration of extracellular vesicles in plasma compared to controls.
- Interleukin-2 (IL2) content was significantly elevated in EVs from ME/CFS cases.
- Pro-inflammatory cytokines CSF2 and TNFα showed positive correlations with fatigue and physical symptom severity in ME/CFS patients.
- Serine protease SERPINA5 (involved in hemostasis) correlated with better self-reported general health scores in ME/CFS cases.
- Machine learning models using 7-20 proteins achieved 79-86% accuracy in distinguishing ME/CFS cases from controls.
Inferred Conclusions
- Extracellular vesicle composition and concentration are objectively altered in ME/CFS, suggesting potential utility as biomarkers.
- Immune dysregulation (elevated pro-inflammatory cytokines) and hemostasis abnormalities are implicated in ME/CFS pathophysiology and correlate with clinical severity.
- Multi-protein signatures can discriminate ME/CFS cases from controls with high accuracy, supporting development of blood-based diagnostic approaches.
- The interconnected alterations in EV cytokines, plasma cytokines, and proteomics indicate complex, system-wide biological disturbance in ME/CFS rather than isolated dysfunction.
Remaining Questions
What This Study Does Not Prove
This study identifies associations between proteins and ME/CFS but does not prove these proteins cause the disease or are directly responsible for symptoms. Machine learning accuracy, while promising, does not establish clinical utility in routine diagnostics without further validation in independent cohorts. The correlations observed do not determine whether immune dysregulation is a primary cause or a secondary consequence of ME/CFS pathophysiology.